文献速递乳腺癌放疗

5次与15次辅助放疗后急性毒性和生活质量的真实世界前瞻性队列研究

Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery - a real-world prospective cohort study.
PubMed 文献 · Radiother Oncol · 2025-11-30

该真实世界前瞻性队列研究纳入2018-2023年荷兰两中心≥50岁接受全乳或部分乳腺照射的乳腺癌患者,比较26 Gy/5次与40 Gy/15次方案的急性毒性和生活质量。结果显示26 Gy方案在急性和乳腺炎及疲劳方面发生率更低,且在整形保乳术后同样如此,3个月和1年患者报告结局可比。

要点

  • 26 Gy/5次较40 Gy/15次的全乳或部分乳腺照射急性≥1级皮炎和疲劳发生率更低。
  • 整形保乳术后26 Gy组≥1级皮炎发生率仍低于40 Gy组(77% vs 94%)。
  • 放疗后3个月和1年两组患者报告结局可比。

核心结论

  • 在真实世界高靶区覆盖条件下,26 Gy/5次方案急性毒性和生活质量与40 Gy/15次方案相当,整形保乳术后亦然。

研究设计与样本

  • 真实世界前瞻性队列研究,纳入2018-2023年荷兰两中心≥50岁接受全乳或部分乳腺照射的乳腺癌女性。
  • 26 Gy/5次组832例(70.2%全乳照射,12.9%整形保乳术),40 Gy/15次组845例(81.9%全乳照射,14.2%整形保乳术)。
  • 急性毒性采用CTCAE v5.0于放疗期间及放疗后≤4周评估,患者报告结局采用EORTC-QLQ-C30/BR23于放疗前、放疗后3个月和1年评估。

主要发现

  • 全乳和部分乳腺照射中,26 Gy组≥1级皮炎和疲劳发生率低于40 Gy组:皮炎61-67% vs 86-91%,疲劳42-43% vs 56%(p < 0.001-0.005)。
  • 整形保乳术后,26 Gy组≥1级皮炎发生率低于40 Gy组(77% vs 94%,p < 0.001)。
  • 放疗后3个月和1年,26 Gy与40 Gy组患者报告结局可比。

临床怎么用

  • 对于≥50岁乳腺癌保乳术后患者,可考虑26 Gy/5次辅助放疗以降低急性皮炎和疲劳。
  • 整形保乳术后选择26 Gy/5次方案时,急性皮炎风险仍低于40 Gy/15次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The FAST-Forward trial demonstrated that 26 Gy in 5 fractions for whole breast irradiation (WBI) has similar outcomes as 40 Gy in 15 fractions. Since radiation treatment plans in the Netherlands in general deliver higher target doses, we aimed to compare acute toxicity and quality of life of the adjuvant 26 Gy and the 40 Gy schedules in a real-world setting, including after oncoplastic surgery. MATERIALS AND METHODS: Eligible were women ≥50 years with breast cancer receiving WBI or partial breast irradiation (PBI) between 2018 and 2023 in two Dutch centres, with either 26 Gy/5 fractions in 1 week or 40 Gy/15 fractions in 3 weeks. Acute toxicity was assessed using CTCAE v5.0 during and ≤ 4 weeks following radiotherapy. Patient-reported outcomes were evaluated using EORTC-QLQ-C30/BR23 prior to radiotherapy, at 3 months and 1 year post-radiotherapy. RESULTS: In total, 832 patients received 26 Gy/5 fractions (70.2% WBI, 12.9% oncoplastic surgery) and 845 patients 40 Gy/15 fractions (81.9% WBI, 14.2% oncoplastic surgery). For WBI and PBI, grade ≥ 1 dermatitis and fatigue were less common after 26 Gy than 40 Gy: 61-67 % versus 86-91% and 42-43% versus 56% respectively (p < 0.001-0.005). After oncoplastic surgery, 26 Gy patients less often experienced grade ≥ 1 dermatitis than 40 Gy patients (77% vs 94%, p < 0.001). At 3 months and 1-year post-radiotherapy, 26 Gy and 40 Gy patients reported comparable patient-reported outcomes. CONCLUSION: We confirmed the safety of the 26 Gy/5 fractions schedule in terms of acute toxicity and quality of life compared to the 40 Gy/15 fractions schedule, also when treated with higher target coverage and following oncoplastic breast-conserving surgery.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mink van der Molen DR, Batenburg MCT, van 't Westeinde T, et al. Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery - a real-world prospective cohort study. Radiother Oncol. 2025. PMID: 41330478. doi:10.1016/j.radonc.2025.111310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。